The FDA approved rituximab (Rituxan, Genentech) in combination with chemotherapy for pediatric patients (≥6 months to <18 years of age) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL).
Efficacy was evaluated in the global multicenter, open-label, randomized Inter-B-NHL Ritux 2010 trial (ClinicalTrials.gov Identifier: NCT01516580). The trial